Elanco Animal Health is a leading global animal health company with a broad product portfolio focused fifty-fifty on Pet Health and Farm Animal segments. Post-2018 spin-off from Eli Lilly and the substantial 2020 Bayer Animal Health acquisition, Elanco has grown into a top-four industry player globally, serving over 90 countries. Its product mix is diversified and includes household names in pet parasiticides (Seresto, Advantage), pain management (Galliprant), dermatology (Zenrelia), and livestock nutrition (Rumensin, Experior). After past integration hurdles and debt-fueled expansion, Elanco has refocused on innovation and operational excellence—delivering eight consecutive quarters of organic revenue growth as of Q2 2025. The company's dual exposure to companion animal and livestock, ongoing ramp of novel products, and a strengthening financial profile (despite high leverage from the Bayer deal) position it to benefit from secular industry growth. However, ongoing execution on debt reduction and commercial uptake of new launches is crucial for full value realization.